NeuroBo Pharmaceuticals News

NeuroBo Pharmaceuticals | DEF 14A: Definitive information statements

Apr 30 08:45 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 30 08:35 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 17 08:34 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Apr 16 16:36 ET

NeuroBo Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers

Apr 12 16:09 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Apr 1 08:31 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 28 08:05 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 13 08:33 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Mar 4 07:35 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 29 08:33 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Feb 14 08:56 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Feb 1 08:31 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash

Jan 18 00:00 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 9 00:00 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Submits Ind Application to the Fda for a Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity

Dec 28, 2023 00:00 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Dec 19, 2023 09:03 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc Posted an Updated Corporate Presentation

Dec 7, 2023 09:20 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023 16:14 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

Nov 6, 2023 08:20 ET

NeuroBo Pharmaceuticals | 8-K: The Board of Directors of Neurobo Pharmaceuticals Appointed Mr. Marshall H. Woodworth as the Company’s Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Oct 30, 2023 08:06 ET